Rare forms of inflammatory myopathies – part I, generalized forms

References

• Neuro wustl home page. neuromuscular.wustl.edu . 2022.
   Google Scholar
• Prieto-Gonzalez S, Grau JM. Diagnosis and classification of granulomatous myositis. Autoimmun Rev. 2014;13(4–5):372–374.
   PubMed Web of Science ®Google Scholar
• Wang JY, Lee LN, Hsueh PR, et al. Tuberculous myositis: a rare but existing clinical entity. Rheumatology (Oxford). 2003;42(7):836–840.
   PubMed Web of Science ®Google Scholar
• Kojan S, Alothman A, Althani Z, et al. Granulomatous myositis associated with brucellosis: a case report and literature review. Muscle Nerve. 2012;45(2):290–293.
   PubMed Web of Science ®Google Scholar
• Roy C, Lai EJ, Lee AHA, et al. Granulomatous myositis as a manifestation of chronic graft-versus-host disease: a case series and review of the literature. Clin Lymphoma Myeloma Leuk. 2022;22(7):e459–e462.
   PubMed Web of Science ®Google Scholar
• Meegada S, Akbar H, Siddamreddy S, et al. Granulomatous myositis associated with extremely elevated anti-striated muscle antibodies in the absence of myasthenia gravis. Cureus. 2020;12(2):e6981.
   PubMed Web of Science ®Google Scholar
• Simmonds NJ, Hoffbrand BI. Contracturing granulomatous myositis: a separate entity. J Neurol Neurosurg Psychiatry. 1990;53(11):998–1000.
   PubMed Web of Science ®Google Scholar
• Thulasidoss K, Sridharan S, Ashokan L, et al. Rare case of sarcoidosis presenting as diffuse contracturing granulomatous myositis on fluorodeoxyglucose positron emission tomography/computed tomography. Indian J Nucl Med. 2018;33(2):2375–2376.
   Web of Science ®Google Scholar
• Sazliyana SS, Jamil A, Kosasih S, et al. Sarcoid myopathy mimicking polymyositis: a case report and pool analysis of the literature reviews. Acta Med Iran. 2017;55(12):800–806.
   PubMedGoogle Scholar
• Care W, Blanc E, Cournac JM, et al. Hypercalcemia revealing diffuse granulomatous myositis. Eur J Nucl Med Mol Imaging. 2017;44(8):1413–1414.
   PubMed Web of Science ®Google Scholar
• Koyama M, Terauchi T, Koizumi M, et al. Granulomatous myositis showing fluctuating “leopard-man” sign: a case report on FDG PET/CT Imaging. Clin Nucl Med. 2019;44(12):961–963.
   PubMed Web of Science ®Google Scholar
• Takanashi T, Suzuki Y, Yoshino Y, et al. Granulomatous myositis: pathologic re-evaluation by immunohistochemical analysis of infiltrating mononuclear cells. J Neurol Sci. 1997;145(1):41–47.
   PubMed Web of Science ®Google Scholar
• Limaye S, Limaye V. Clinical characteristics of myositis associated with graft-versus-host disease. Curr Rheumatol Rep. 2021;23(5):30.
   PubMed Web of Science ®Google Scholar
• Wilkinson M, Yeung D, Limaye V. Case of inflammatory myopathy in graft vs host disease - A potential role for ibrutinib. Neuromuscul Disord. 2021;31(9):865–869.
   PubMed Web of Science ®Google Scholar
• Maillard-Lefebvre H, Morell-Dubois S, Lambert M, et al. Graft-versus-host disease-related polymyositis. Clin Rheumatol. 2010;29(4):431–433.
   PubMed Web of Science ®Google Scholar
• New-Tolley J, Smith C, Koszyca B, et al. Inflammatory myopathies after allogeneic stem cell transplantation. Muscle Nerve. 2018;58(6):790–795.
   PubMed Web of Science ®Google Scholar
• Takahashi K, Kashihara K, Shinagawa K, et al. Myositis as a manifestation of chronic graft-versus-host disease. Intern Med. 2000;39(6):482–485.
   PubMed Web of Science ®Google Scholar
• Couriel DR, Beguelin GZ, Giralt S, et al. Chronic graft-versus-host disease manifesting as polymyositis: an uncommon presentation. Bone Marrow Transplant. 2002;30(8):543–546.
   PubMed Web of Science ®Google Scholar
• Shahzad M, Chaudhary SG, Basit A, et al. Chronic graft-versus-host disease presenting as acute polymyositis: a case series and systematic review. Transpl Immunol. 2022;70:101520.
   PubMed Web of Science ®Google Scholar
• Cuvelier GDE, Schoettler M, Buxbaum NP, et al. Toward a better understanding of the atypical features of chronic graft-versus-host disease: a report from the 2020 National Institutes of Health Consensus Project Task Force. Transplant Cell Ther 2022.
   Google Scholar
• Sakamoto K, Imamura T, Niwa F, et al. Dermatomyositis developed in a recipient of allogeneic BMT; the differentiation of chronic GVHD and autoimmune disease. Bone Marrow Transplant. 2012;47(4):603–604.
   PubMed Web of Science ®Google Scholar
• Stevens AM. Stevens AM foreign cells in polymyositis: could stem cell transplantation and pregnancy-derived chimerism lead to the same disease? Curr Rheumatol Rep. 2003;5(6):437–444.
   PubMedGoogle Scholar
• Michelis FV, Bril V, Lipton JH. A case report and literature review of chronic graft-versus-host disease manifesting as polymyositis. Int J Hematol. 2015;102(1):144–146.
   PubMed Web of Science ®Google Scholar
• Franklin C, Livingstone E, Roesch A, et al. Schadendorf D Immunotherapy in melanoma: recent advances and future directions. Eur J Surg Oncol. 2017;43(3):604–611.
   PubMed Web of Science ®Google Scholar
• Kim BJ, Kim JH, Kim HS. Survival benefit of immune checkpoint inhibitors according to the histology in non-small-cell lung cancer: a meta-analysis and review. Oncotarget. 2017;8(31):51779–51785.
   PubMedGoogle Scholar
• Hamada N, Maeda A, Takase-Minegishi K, et al. Incidence and distinct features of immune checkpoint inhibitor-related myositis from idiopathic inflammatory myositis: a single-center experience with systematic literature review and meta-analysis. Front Immunol. 2021;12:803410.
   PubMed Web of Science ®Google Scholar
• Shelly S, Triplett JD, Pinto MV, et al. Immune checkpoint inhibitor-associated myopathy: a clinicoseropathologically distinct myopathy. Brain Commun. 2020;2(2):fcaa181.
   PubMedGoogle Scholar
• Pathak R, Katel A, Massarelli E, et al. Immune checkpoint inhibitor–induced myocarditis with myositis/myasthenia gravis overlap syndrome: a systematic review of cases. The Oncologist. 2021;26(12):1052–1061.
   PubMed Web of Science ®Google Scholar
• Aldrich J, Pundole X, Tummala S, et al. Inflammatory myositis in cancer patients receiving immune checkpoint inhibitors. Arthritis Rheumatol. 2021;73(5):866–874.
   PubMed Web of Science ®Google Scholar
• Alexander S, Swami U, Kaur A, et al. Safety of immune checkpoint inhibitors in patients with cancer and pre-existing autoimmune disease. Ann Transl Med. 2021;9(12):1033.
   PubMed Web of Science ®Google Scholar
• Kadota H, Gono T, Shirai Y, et al. Immune checkpoint inhibitor-induced myositis: a case report and literature review. Curr Rheumatol Rep. 2019;21(4):10.
   PubMed Web of Science ®Google Scholar
• Kostine M, Finckh A, Bingham CO, et al. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Ann Rheum Dis. 2021;80(1):36–48.
   PubMed Web of Science ®Google Scholar
• Huang YT, Chen YP, Lin WC, et al. Sun YT immune checkpoint inhibitor-induced myasthenia gravis. Front Neurol. 2020;11:634.
   PubMed Web of Science ®Google Scholar
• Palaskas N, Lopez-Mattei J, Durand JB, et al. Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment. J Am Heart Assoc. 2020;9(2):e013757.
   PubMed Web of Science ®Google Scholar
• Seki M, Uruha A, Ohnuki Y, et al. Inflammatory myopathy associated with PD-1 inhibitors. J Autoimmun. 2019;100:105–113.
   PubMed Web of Science ®Google Scholar
• Touat M, Maisonobe T, Knauss S, et al. Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. Neurology. 2018;91(10):e985–e994.
   PubMed Web of Science ®Google Scholar
• Matas-Garcia A, Milisenda JC, Selva-O’Callaghan A, et al. Emerging PD-1 and PD-1L inhibitors-associated myopathy with a characteristic histopathological pattern. Autoimmun Rev. 2020;19(2):102455.
   PubMed Web of Science ®Google Scholar
• Ammirati E, Buono A, Moroni F, et al. State-of-the-art of endomyocardial biopsy on acute myocarditis and chronic inflammatory cardiomyopathy. Curr Cardiol Rep. 2022;24(5):597–609.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2018;36(17):1714–1768.
   PubMed Web of Science ®Google Scholar
• Esfahani K, Buhlaiga N, Thã©bault P, et al. Alemtuzumab for immune-related myocarditis due to PD-1 therapy. N Engl J Med. 2019;380(24):2375–2376.
   PubMed Web of Science ®Google Scholar
• Salem JE, Allenbach Y, Vozy A, et al. Abatacept for severe immune checkpoint inhibitor-associated myocarditis. N Engl J Med. 2019;380(24):2377–2379.
   PubMed Web of Science ®Google Scholar
• Allenbach Y, Anquetil C, Manouchehri A, et al. Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities. Autoimmun Rev. 2020;19(8):102586.
   PubMed Web of Science ®Google Scholar
• Shiba H, Takeuchi T, Isoda K, et al. Dermatomyositis as a complication of interferon-α therapy: a case report and review of the literature. Rheumatol Int. 2014;34(9):1319–1322.
   PubMed Web of Science ®Google Scholar
• Narayanappa G, Nandeesh BN. Infective myositis. Brain Pathol. 2021;31(3):e12950.
   PubMed Web of Science ®Google Scholar
• Maramattom BV, Syed AA. Viral neuromyopathy associated with acute hepatitis B infection. BMJ Case Rep. 2022;15(1):e247203.
   Google Scholar
• Gibson SB, Majersik JJ, Smith AG, et al. Three cases of acute myositis in adults following influenza-like illness during the H1N1 pandemic. J Neurosci Rural Pract. 2013;4(1):51–54.
   PubMedGoogle Scholar
• Tanaka T, Takada T, Takagi D, et al. Acute renal failure due to rhabdomyolysis associated with echovirus 9 infection: a case report and review of literature. Jpn J Med. 1989;28(2):237–242.
   PubMedGoogle Scholar
• Capasso M, Di MA, Comar M, et al. The association of chronic hepatitis B and myopathy. Neurology. 2006;67(8):1467–1469.
   PubMed Web of Science ®Google Scholar
• Flores-Chavez A, Carrion JA, Forns X. Extrahepatic manifestations associated with chronic hepatitis C virus infection. Rev Esp Sanid Penit. 2017;19(3):87–97.
   PubMedGoogle Scholar
• Younis LK, Talaat FM, Deif AH, et al. Immunohistochemical detection of HCV in nerves and muscles of patients with HCV associated peripheral neuropathy and myositis. Int J Health Sci (Qassim). 2007;1(2):195–202.
   PubMedGoogle Scholar
• Di MA, Bonetti B, Capasso M, et al. Hepatitis C virus infection and myositis: a virus localization study. Neuromuscul Disord. 2003;13(1):68–71.
   PubMed Web of Science ®Google Scholar
• Lloyd TE, Pinal-Fernandez I, Michelle EH, et al. Overlapping features of polymyositis and inclusion body myositis in HIV-infected patients. Neurology. 2017;88(15):1454–1460.
   PubMed Web of Science ®Google Scholar
• Tsuruta Y, Yamada T, Yoshimura T, et al. Inclusion body myositis associated with hepatitis C virus infection. Fukuoka Igaku Zasshi. 2001;92(11):370–376.
   PubMedGoogle Scholar
• Nguyen BY, Reveille JD. Rheumatic manifestations associated with HIV in the highly active antiretroviral therapy era. Curr Opin Rheumatol. 2009;21(4):404–410.
   PubMed Web of Science ®Google Scholar
• Johnson RW, Williams FM, Kazi S, et al. Human immunodeficiency virus-associated polymyositis: a longitudinal study of outcome. Arthritis Rheum. 2003;49(2):172–178.
   PubMedGoogle Scholar
• Carroll MB. Dermatomyositis and HIV infection: case report and review of the literature. Rheumatol Int. 2011;31(5):673–679.
   PubMed Web of Science ®Google Scholar
• Landon-Cardinal O, Gallay L, Dubourg O, et al. Expanding the spectrum of HIV-associated myopathy. J Neurol Neurosurg Psychiatry. 2019;90(11):1296–1298.
   PubMed Web of Science ®Google Scholar
• Pires RE, Reis IGN, Waldolato GS, et al. What do we need to know about musculoskeletal manifestations of COVID-19?: a systematic review. JBJS Rev. 2022;10(6). DOI:10.2106/JBJS.RVW.22.00013
   PubMed Web of Science ®Google Scholar
• Hannah JR, Ali SS, Nagra D, et al. Skeletal muscles and Covid-19: a systematic review of rhabdomyolysis and myositis in SARS-CoV-2 infection. Clin Exp Rheumatol. 2022;40(2):329–338.
   PubMed Web of Science ®Google Scholar
• Maiese A, Manetti AC, La RR, et al. Autopsy findings in COVID-19-related deaths: a literature review. Forensic Sci Med Pathol. 2021;17(2):375–376.
   PubMed Web of Science ®Google Scholar
• Movahedi N, Ziaee V. COVID-19 and myositis; true dermatomyositis or prolonged post viral myositis? Pediatr Rheumatol Online J. 2021;19(1):86.
   PubMed Web of Science ®Google Scholar
• Dalakas MC. Unconvincing evidence of SARS-CoV-2-associated myositis in autopsied muscles. JAMA Neurol. 2022;79:92.
   PubMed Web of Science ®Google Scholar
• Byler J, Harrison R. Rhabdomyolysis following recovery from severe COVID-19: a case report. Am J Case Rep. 2021;22:e931616.
   PubMed Web of Science ®Google Scholar
• Sacchi MC, Tamiazzo S, Lauritano EC. Bonometti R Case report of COVID-19 in an elderly patient: could SARS-CoV2 trigger myositis? Eur Rev Med Pharmacol Sci. 2020;24(22):11960–11963.
   PubMed Web of Science ®Google Scholar
• Saud A, Naveen R, Aggarwal R, et al. COVID-19 and myositis: what we know so far. Curr Rheumatol Rep. 2021;23(8):63.
   PubMed Web of Science ®Google Scholar
• Qian J, Xu H. COVID-19 disease and dermatomyositis: a mini-review. Front Immunol. 2021;12:747116.
   PubMed Web of Science ®Google Scholar
• Dalakas MC. Inflammatory myopathies: update on diagnosis, pathogenesis and therapies, and COVID-19-related implications. Acta Myol. 2020;39(4):289–301.
   PubMedGoogle Scholar
• Mehan WA, Yoon BC, Lang M, et al. Paraspinal myositis in patients with COVID-19 infection. AJNR Am J Neuroradiol. 2020;41(10):1949–1952.
   PubMed Web of Science ®Google Scholar
• Veyseh M, Koyoda S, Ayesha B. COVID-19 IgG-related autoimmune inflammatory necrotizing myositis. BMJ Case Rep. 2021;14(4):e239457.
   Google Scholar
• De SM, Isailovic N, Motta F, et al. Environmental triggers for connective tissue disease: the case of COVID-19 associated with dermatomyositis-specific autoantibodies. Curr Opin Rheumatol. 2021;33(6):514–521.
   PubMed Web of Science ®Google Scholar
• Suh J, Mukerji SS, Collens SI, et al. Skeletal muscle and peripheral nerve histopathology in COVID-19. Neurology. 2021;97(8):e849–e858.
   PubMed Web of Science ®Google Scholar
• Tanboon J, Nishino I. COVID −19-associated myositis may be dermatomyositis. Muscle Nerve. 2021;63(1):E9–E10.
   PubMed Web of Science ®Google Scholar
• Uslu S. Myositis due to COVID-19. Postgrad Med J. 2021;97(1148):399
   PubMed Web of Science ®Google Scholar
• Park J, Lee MJ, Kim N, et al. Risk factors for extraophthalmic involvement and treatment outcomes in patients with IgG4-related ophthalmic disease. Br J Ophthalmol. 2018;102(6):736–741.
   PubMed Web of Science ®Google Scholar
• Gono T, Sato S, Kawaguchi Y, et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology (Oxford). 2012;51(9):1563–1570.
   PubMed Web of Science ®Google Scholar
• Borges NH, Godoy TM, Kahlow BS. Onset of dermatomyositis in close association with COVID-19-a first case reported. Rheumatology (Oxford). 2021;60(SI):SI96–SI96. SI96.
   PubMedGoogle Scholar
• Bassez G, Authier FJ, Lechapt-Zalcman E, et al. Inflammatory myopathy with abundant macrophages (IMAM): a condition sharing similarities with cytophagic histiocytic panniculitis and distinct from macrophagic myofasciitis. J Neuropathol Exp Neurol. 2003;62:464–474.
   PubMed Web of Science ®Google Scholar
• Gherardi RK, Authier FJ. Macrophagic myofasciitis: characterization and pathophysiology. Lupus. 2012;21(2):184–189.
   PubMed Web of Science ®Google Scholar
• Brunn A, Hans VJ, Vogelgesang S, et al. Inflammatory myopathy with abundant macrophages and dermatomyositis: two stages of one disorder or two distinct entities? Acta Neuropathol. 2009;118(6):793–801.
   PubMed Web of Science ®Google Scholar
• Hara S, Henmi T, Kawakami A, et al. Clinical, serologic and magnetic resonance imaging of 3 cases of inflammatory myopathy with abundant macrophages in the Japanese population. Rheumatol Int. 2013;33(4):1059–1064.
   PubMed Web of Science ®Google Scholar
• Carrera E, Lobrinus JA, Spertini O, et al. Dermatomyositis, lobar panniculitis and inflammatory myopathy with abundant macrophages. Neuromuscul Disord. 2006;16(7):468–471.
   PubMed Web of Science ®Google Scholar
• Richardson SJ, Lopez F, Rojas S, et al. Multinodular polymyositis in a patient with human immunodeficiency and hepatitis C virus coinfection. Muscle Nerve. 2001;24(3):433–437.
   PubMed Web of Science ®Google Scholar
• Brown P, Doyle DV. Localized nodular myositis as the first manifestation of polymyositis. Br J Rheumatol. 1989;28(1):84.
   PubMedGoogle Scholar
• Heffner RR Jr. Barron SA Polymyositis beginning as a focal process. Arch Neurol. 1981;38(7):439–442.
   PubMedGoogle Scholar
• Anan R, Akiyama M, Kaneko Y, et al. Polymyositis with elevated serum IgG4 levels and abundant IgG4+ plasma cell infiltration: a case report and literature review. Medicine (Baltimore). 2017;96(48):e8710.
   PubMed Web of Science ®Google Scholar
• Casteleyn V, Radbruch H, Diekhoff T, et al. Immunoglobulin (Ig)G-4 related myositis - A new entity? Neuromuscul Disord. 2019;29(1):70–74.
   PubMed Web of Science ®Google Scholar
• Pestronk A, Sinha N, Alhumayyd Z, et al. Immune myopathy with large histiocyte-related myofiber necrosis. Neurology. 2019;92(15):e1763–e1772.
   PubMed Web of Science ®Google Scholar
• Kurland EM, Kurland LT, Mulder DW, et al. Lack of association of A/NJ/76 (swine flu) vaccine and polymyositis. Neuroepidemiology. 1985;4(3):125–137.
   PubMedGoogle Scholar
• Stübgen J-P. A review on the association between inflammatory myopathies and vaccination. Autoimmun Rev. 2014;13(1):31–39.
   PubMed Web of Science ®Google Scholar
• Vutipongsatorn K, Isaacs A, Farah Z. Inflammatory myopathy occurring shortly after severe acute respiratory syndrome coronavirus 2 vaccination: two case reports. J Med Case Rep. 2022;16(1):57.
   PubMedGoogle Scholar
• Venkateswaran K, Aw DC, Huang J. Dermatomyositis following COVID-19 vaccination. Dermatol Ther. 2022;35:e15479.
   PubMed Web of Science ®Google Scholar
• Tan CY, Toh TH, Toh YF, et al. A temporal association between COVID-19 vaccination and immune-mediated necrotizing myopathy. Muscle Nerve. 2022;65(6):E24–E26.
   PubMed Web of Science ®Google Scholar
• Al-Rasbi S, Al-Maqbali JS, Al-Farsi R, et al. Myocarditis, pulmonary hemorrhage, and extensive myositis with rhabdomyolysis 12 days after first dose of pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine: a case report. Am J Case Rep. 2022;23:e934399.
   PubMed Web of Science ®Google Scholar
• Gouveia J, Barros C, Caldeira M, et al. Inflammatory myopathy secondary to SARS-CoV-2 vaccination. Isr Med Assoc J. 2022;24(7):444.
   PubMed Web of Science ®Google Scholar
• Gouda W, Albasri A, Alsaqabi F, et al. Dermatomyositis following BNT162b2 mRNA COVID-19 vaccination. J Korean Med Sci. 2022;37(5):e32.
   PubMed Web of Science ®Google Scholar
• Ramalingam S, Arora H, Lewis S, et al. COVID-19 vaccine-induced cellulitis and myositis. Cleve Clin J Med. 2021;88(12):648–650.
   PubMed Web of Science ®Google Scholar
• Theodorou DJ, Theodorou SJ, Axiotis A, et al. COVID-19 vaccine-related myositis. Qjm. 2021;114(6):424–425.
   PubMed Web of Science ®Google Scholar
• Kim JH, Kim JH, Woo CG. Clinicopathological characteristics of inflammatory myositis induced by COVID-19 vaccine (Pfizer-BioNTech BNT162b2): a case report. J Korean Med Sci. 2022;37(11):e91.
   PubMed Web of Science ®Google Scholar
• Conticini E, d’Alessandro M, Grazzini S, et al. Relapses of idiopathic inflammatory myopathies after vaccination against COVID-19: a real-life multicenter Italian study. Intern Emerg Med. 2022;17:1–8.
   Web of Science ®Google Scholar
• Sprow G, Afarideh M, Dan J, et al. Autoimmune skin disease exacerbations following COVID-19 vaccination. Front Immunol. 2022;13:899526.
   PubMed Web of Science ®Google Scholar
• Fermon C, Authier FJ, Gallay L. Idiopathic eosinophilic myositis: a systematic literature review. Neuromuscul Disord. 2022;32(2):116–124.
   PubMed Web of Science ®Google Scholar
• Selva-O’Callaghan A, Trallero-Araguás E, Grau JM. Eosinophilic myositis: an updated review. Autoimmun Rev. 2014;13(4–5):375–378.
   PubMed Web of Science ®Google Scholar
• Bou KR, Abou SM, Sissi S, et al. Methimazole-induced myositis: a case report and review of the literature. Endocrinol Diabetes Metab Case Rep. 2013;2013:130008.
   PubMedGoogle Scholar
• Trueb RM, Pericin M, Winzeler B. Wüthrich B, Burg G Eosinophilic myositis/perimyositis: frequency and spectrum of cutaneous manifestations. J Am Acad Dermatol. 1997;37(3):385–391.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zeng Y, Xie Y, et al. Eosinophilic fasciitis associated with myositis: report of four cases and review of the literature. Australas J Dermatol. 2019;60(3):e227–e231.
   PubMed Web of Science ®Google Scholar
• Igarashi R, Irisawa A, Shibukawa G, et al. Eosinophilic esophageal myositis diagnosed by endoscopic ultrasound-guided fine-needle aspiration biopsy: a case report. Clin J Gastroenterol. 2016;9(5):285–288.
   PubMedGoogle Scholar
• Sato H, Nakajima N, Takahashi K, et al. Proposed criteria to differentiate heterogeneous eosinophilic gastrointestinal disorders of the esophagus, including eosinophilic esophageal myositis. World J Gastroenterol. 2017;23(13):2414–2423.
   PubMed Web of Science ®Google Scholar
• Emslie-Smith AM. Necrotizing myopathy with pipestem capillaries, microvascular deposition of the complement membrane attack complex (MAC), and minimal cellular infiltration. Neurology. 1991;41(6):936–939.
   PubMed Web of Science ®Google Scholar
• Reimann J, Kornblum C, Tolksdorf K. Brück W, van Landeghem FK Myopathy and neuropathy with pipestem capillaries and vascular activated complement deposition. Neurology. 2011;77(4):401–403.
   PubMed Web of Science ®Google Scholar
• Schroder NW, Goebel HH, Brandis A, et al. Pipestem capillaries in necrotizing myopathy revisited. Neuromuscul Disord. 2013;23(1):66–74.
   PubMed Web of Science ®Google Scholar
• Hou Y, Liu M, Luo YB, et al. Idiopathic inflammatory myopathies with anti-mitochondrial antibodies: clinical features and treatment outcomes in a Chinese cohort. Neuromuscul Disord. 2019;29(1):5–13.
   PubMed Web of Science ®Google Scholar
• Maeda MH, Tsuji S, Shimizu J. Inflammatory myopathies associated with anti-mitochondrial antibodies. Brain. 2012;135(6):1767–1777.
   PubMedGoogle Scholar
• Albayda J, Khan A, Casciola-Rosen L, et al. Christopher-Stine L Inflammatory myopathy associated with anti-mitochondrial antibodies: a distinct phenotype with cardiac involvement. Semin Arthritis Rheum. 2018;47(4):552–556.
   PubMed Web of Science ®Google Scholar
• Mauhin W, Mariampillai K, Allenbach Y, et al. Benveniste O Anti-mitochondrial antibodies are not a hallmark of severity in idiopathic inflammatory myopathies. Joint Bone Spine. 2018;85(3):375–376.
   PubMed Web of Science ®Google Scholar
• Minamiyama S, Ueda S, Nakashima R, et al. Thigh muscle MRI findings in myopathy associated with anti-mitochondrial antibody. Muscle Nerve. 2020;61(1):81–87.
   PubMed Web of Science ®Google Scholar
• Liu M, Hou Y, Dai T, et al. The clinical and histopathological features of idiopathic inflammatory myopathies with asymmetric muscle involvement. J Clin Neurosci. 2019;65:46–53.
   PubMed Web of Science ®Google Scholar
• Melzer N, Wessig C, Ulzheimer J, et al. Distal-symmetric focal inflammatory myopathy distinct from focal myositis and polymyositis. Muscle Nerve. 2009;40(2):309–312.
   PubMed Web of Science ®Google Scholar
• Chariot P, Ruet E, Authier F-J, et al. Cytochrome c oxidase deficiencies in the muscle of patients with inflammatory myopathies. Acta Neuropathol. 1996;91(5):530–536.
   PubMed Web of Science ®Google Scholar
• Blume G, Pestronk A, Frank B. Polymyositis with cytochrome oxidase negative muscle fibres. Early quadriceps weakness and poor response to immunosuppressive therapy. Brain. 1997;120(Pt 1):39–45.
   PubMedGoogle Scholar
• Scangarello FA, Angel-Buitrago L, Lang-Orsini M, et al. Giant cell myositis associated with concurrent myasthenia gravis: a case-based review of the literature. Clin Rheumatol. 2021;40(9):3841–3851.
   PubMed Web of Science ®Google Scholar
• Yawar B, Malik Z, Naz F A. Rare case of orbital myositis. J Ayub Med Coll Abbottabad. 2020;32(Suppl 1):S706–S708.
   Google Scholar
• Mohsin M, Mahmud S. Omicron SARS-CoV-2 variant of concern: a review on its transmissibility, immune evasion, reinfection, and severity. Medicine (Baltimore). 2022;101(19):e29165.
   PubMed Web of Science ®Google Scholar